Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD). The IND clearance enables initiation of a clinical trial of VY1706 in adults with early AD; dosing is expected to begin in the second half of the year.